USJC Statement for the Recent Novel Coronavirus Outbreak

The novel coronavirus (COVID-19) outbreak is now having an increased impact on business, events, and travel in the United States, Japan and beyond. The U.S.-Japan Council (USJC) continues to monitor the developing COVID-19 situation in Japan and the United States and to implement the expert recommendations of national and international authorities including the World Health Organization (WHO), United States Centers for Disease Control and Prevention (CDC), and Japanese Ministry of Health, Labour and Welfare (MHLW).

USJC’s highest priority is the safety of all participants and the effectiveness of our programs. As the situation evolves and new information and guidelines from the WHO, CDC, and/or MHLW are released, USJC will coordinate with stakeholders and donors to determine whether to continue, cancel, or postpone each program on a case-by-case basis.

In all events, USJC will ask participants, stakeholders, donors, and third party vendors to follow best practice recommendations for health and safety, including:

  • Hand sanitizer and soap and water should be easily accessible and frequently utilized.
  • All participants, stakeholders, donors, and third party vendors should adopt WHO, CDC, and other health and safety best practices.
  • Participants who meet one or more of the following should not attend the events:
    • Traveled in any area with widespread or ongoing community spread (CDC Level 3 health notice: https://wwwnc.cdc.gov/travel/notices) within 14 days of the program start date;
    • Had contact with someone who has been  in any area with widespread or ongoing community spread (CDC Level 3 health notice) within 14 days of the program start date; or
    • Have a fever, cough, difficulty breathing, other signs of sickness, or is otherwise feeling unwell.

For further information about USJC programs, please contact your program manager or USJC in by phone at (Japan: 03-4510-3400; U.S.: 202-223-6840) , or fax (Japan: 03-4510-3419; U.S.: 202-280-1235).